Cargando…

Prognostic Model for Intracranial Progression after Stereotactic Radiosurgery: A Multicenter Validation Study

SIMPLE SUMMARY: To optimize surveillance for patients with brain metastases following stereotactic radiosurgery (SRS), we sought to validate a previously published nomogram estimating post-SRS intracranial progression (IP) risk. Among 890 patients completing an initial SRS course across two institut...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpenter, David J., Natarajan, Brahma, Arshad, Muzamil, Natesan, Divya, Schultz, Olivia, Moravan, Michael J., Read, Charlotte, Lafata, Kyle J., Giles, Will, Fecci, Peter, Mullikin, Trey C., Reitman, Zachary J., Kirkpatrick, John P., Floyd, Scott R., Chmura, Steven J., Hong, Julian C., Salama, Joseph K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657742/
https://www.ncbi.nlm.nih.gov/pubmed/36358606
http://dx.doi.org/10.3390/cancers14215186
Descripción
Sumario:SIMPLE SUMMARY: To optimize surveillance for patients with brain metastases following stereotactic radiosurgery (SRS), we sought to validate a previously published nomogram estimating post-SRS intracranial progression (IP) risk. Among 890 patients completing an initial SRS course across two institutions 7/2017–12/2020, 53% were deemed high-risk for IP. Freedom from IP was superior for low-risk patients (p < 0.001), with a median of 13.9 months (95% CI 11.1–17.1 months) versus 7.6 months (95% CI 6.4–9.3 months) for high-risk patients. This large multisite cohort supports the use of an IP nomogram as a quick, simple means of stratifying patients into low- and high-risk groups for post-SRS IP. ABSTRACT: Stereotactic radiosurgery (SRS) is a standard of care for many patients with brain metastases. To optimize post-SRS surveillance, this study aimed to validate a previously published nomogram predicting post-SRS intracranial progression (IP). We identified consecutive patients completing an initial course of SRS across two institutions between July 2017 and December 2020. Patients were classified as low- or high-risk for post-SRS IP per a previously published nomogram. Overall survival (OS) and freedom from IP (FFIP) were assessed via the Kaplan–Meier method. Assessment of parameters impacting FFIP was performed with univariable and multivariable Cox proportional hazard models. Among 890 patients, median follow-up was 9.8 months (95% CI 9.1–11.2 months). In total, 47% had NSCLC primary tumors, and 47% had oligometastatic disease (defined as ≤5 metastastic foci) at the time of SRS. Per the IP nomogram, 53% of patients were deemed high-risk. For low- and high-risk patients, median FFIP was 13.9 months (95% CI 11.1–17.1 months) and 7.6 months (95% CI 6.4–9.3 months), respectively, and FFIP was superior in low-risk patients (p < 0.0001). This large multisite BM cohort supports the use of an IP nomogram as a quick and simple means of stratifying patients into low- and high-risk groups for post-SRS IP.